|
100 |
From missing Analysis to Brand Protection Violations - FDA Warning Letter to Canadian Manufacturer
|
sureAssist |
2025-01-02 |
1,300 |
|
99 |
Risk Analysis in Case of Insufficient Process Validation
|
sureAssist |
2025-01-02 |
1,195 |
|
98 |
Microbiological monitoring: Adapting to new rapid methods regulatory demands
|
sureAssist |
2025-01-02 |
1,152 |
|
97 |
Count On Data Integrity Auditors Making These 10 Requests
|
sureAssist |
2025-01-02 |
1,107 |
|
96 |
What To Do When Your Regulatory Findings Need Quality Risk Management Action
|
sureAssist |
2024-12-26 |
1,128 |
|
95 |
The cleanroom debate: Epoxy flooring vs raised flooring
|
sureAssist |
2024-12-26 |
1,221 |
|
94 |
Inadequate Classification leads to Warning Letter
|
sureAssist |
2024-12-26 |
937 |
|
93 |
FDA criticises the Use of pharmaceutical Facilities for industrial Products
|
sureAssist |
2024-12-26 |
932 |
|
92 |
GMP Requirements for Ready to Sterilize (RTS) and Ready to Use (RTU) Containers
|
sureAssist |
2024-12-26 |
975 |
|
91 |
Modular vs panellised: A guide to accelerate cleanroom delivery
|
sureAssist |
2024-12-26 |
992 |
